Laura Parkkinen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4020267/publications.pdf

Version: 2024-02-01

38 papers	5,572 citations	147801 31 h-index	315739 38 g-index
40 all docs	40 docs citations	40 times ranked	6979 citing authors

#	Article	IF	Citations
1	Cerebrospinal Fluid Î²-Amyloid 42 and Tau Proteins as Biomarkers of Alzheimer-Type Pathologic Changes in the Brain. Archives of Neurology, 2009, 66, 382-9.	4.5	747
2	Glucocerebrosidase mutations in clinical and pathologically proven Parkinson's disease. Brain, 2009, 132, 1783-1794.	7.6	612
3	Lewy- and Alzheimer-type pathologies in Parkinson's disease dementia: which is more important?. Brain, 2011, 134, 1493-1505.	7.6	497
4	Alphaâ€synuclein <scp>RT</scp>â€Qu<scp>IC</scp> in the <scp>CSF</scp> of patients with alphaâ€synucleinopathies. Annals of Clinical and Translational Neurology, 2016, 3, 812-818.	3.7	388
5	Applicability of current staging/categorization of Î±-synuclein pathology and their clinical relevance. Acta Neuropathologica, 2008, 115, 399-407.	7.7	294
6	Deficits in dopaminergic transmission precede neuron loss and dysfunction in a new Parkinson model. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, E4016-25.	7.1	259
7	Staging/typing of Lewy body related Î±-synuclein pathology: a study of the BrainNet Europe Consortium. Acta Neuropathologica, 2009, 117, 635-652.	7.7	249
8	Morphogenesis of Lewy Bodies: Dissimilar Incorporation of Î±-Synuclein, Ubiquitin, and p62. Journal of Neuropathology and Experimental Neurology, 2003, 62, 1241-1253.	1.7	240
9	Genome sequencing analysis identifies new loci associated with Lewy body dementia and provides insights into its genetic architecture. Nature Genetics, 2021, 53, 294-303.	21.4	198
10	Investigating the genetic architecture of dementia with Lewy bodies: a two-stage genome-wide association study. Lancet Neurology, The, 2018, 17, 64-74.	10.2	195
11	Genetic analysis implicates APOE, SNCA and suggests lysosomal dysfunction in the etiology of dementia with Lewy bodies. Human Molecular Genetics, 2014, 23, 6139-6146.	2.9	178
12	Testing an aetiological model of visual hallucinations in Parkinson's disease. Brain, 2011, 134, 3299-3309.	7.6	132
13	Parkin Disease. JAMA Neurology, 2013, 70, 571.	9.0	119
14	Generation and characterization of novel conformation-specific monoclonal antibodies for Î±-synuclein pathology. Neurobiology of Disease, 2015, 79, 81-99.	4.4	116
15	Regional Distribution of Î±-Synuclein Pathology in Unimpaired Aging and Alzheimer Disease. Journal of Neuropathology and Experimental Neurology, 2003, 62, 363-367.	1.7	109
16	Neuropathological consensus criteria for the evaluation of Lewy pathology in post-mortem brains: a multi-centre study. Acta Neuropathologica, 2021, 141, 159-172.	7.7	107
17	Disentangling the Relationship between Lewy Bodies and Nigral Neuronal Loss in Parkinson's Disease. Journal of Parkinson's Disease, 2011, 1, 277-286.	2.8	106
18	Î±â€synuclein genetic variability: A biomarker for dementia in Parkinson disease. Annals of Neurology, 2016, 79, 991-999.	5.3	85

#	Article	IF	Citations
19	The Significance of Î±-Synuclein, Amyloid-Î² and Tau Pathologies in Parkinson's Disease Progression and Related Dementia. Neurodegenerative Diseases, 2014, 13, 154-156.	1.4	83
20	Assessment of Î±-Synuclein Pathology: A Study of the BrainNet Europe Consortium. Journal of Neuropathology and Experimental Neurology, 2008, 67, 125-143.	1.7	73
21	Neuropathological evidence of body-first vs. brain-first Lewy body disease. Neurobiology of Disease, 2021, 161, 105557.	4.4	72
22	Widespread and abundant Î±â€šynuclein pathology in a neurologically unimpaired subject. Neuropathology, 2005, 25, 304-314.	1.2	71
23	Î±â€šynuclein pathology is highly dependent on the case selection. Neuropathology and Applied Neurobiology, 2001, 27, 314-325.	3.2	69
24	DNM3 and genetic modifiers of age of onset in LRRK2 Gly2019Ser parkinsonism: a genome-wide linkage and association study. Lancet Neurology, The, 2016, 15, 1248-1256.	10.2	69
25	Diagnostic value of cerebrospinal fluid alpha-synuclein seed quantification in synucleinopathies. Brain, 2022, 145, 584-595.	7.6	65
26	DNAJC12 and dopaâ€responsive nonprogressive parkinsonism. Annals of Neurology, 2017, 82, 640-646.	5.3	60
27	<scp>G</scp>ut <scp>F</scp>eelings <scp>Ab</scp>out Î±â€<scp>S</scp>ynuclein in <scp>G</scp>astrointestinal <scp>B</scp>iopsies: <scp>B</scp>iomarker in the <scp>M</scp>aking?. Movement Disorders, 2016, 31, 193-202.	3.9	56
28	MAPT Genetic Variation and Neuronal Maturity Alter Isoform Expression Affecting Axonal Transport in iPSC-Derived Dopamine Neurons. Stem Cell Reports, 2017, 9, 587-599.	4.8	53
29	Region-specific deficits in dopamine, but not norepinephrine, signaling in a novel A30P Î±-synuclein BAC transgenic mouse. Neurobiology of Disease, 2014, 62, 193-207.	4.4	46
30	Glucocerebrosidase mutations do not cause increased Lewy body pathology in Parkinson's disease. Molecular Genetics and Metabolism, 2011, 103, 410-412.	1.1	40
31	Detection of alphaâ€synuclein conformational variants from gastroâ€intestinal biopsy tissue as a potential biomarker for Parkinson's disease. Neuropathology and Applied Neurobiology, 2018, 44, 722-736.	3.2	39
32	Heritability and genetic variance of dementia with Lewy bodies. Neurobiology of Disease, 2019, 127, 492-501.	4.4	29
33	Systematic Appraisal Using Immunohistochemistry of Brain Pathology in Aged and Demented Subjects. Dementia and Geriatric Cognitive Disorders, 2008, 25, 423-432.	1.5	23
34	Can olfactory bulb biopsy be justified for the diagnosis of Parkinsonâ€™s disease? Comments on â€œolfactory bulb Î±-synucleinopathy has high specificity and sensitivity for Lewy body disordersâ€. Acta Neuropathologica, 2009, 117, 213-214.	7.7	23
35	<scp>Humanâ€Specific</scp> Transcriptome of Ventral and Dorsal Midbrain Dopamine Neurons. Annals of Neurology, 2020, 87, 853-868.	5.3	22
36	Concomitant progressive supranuclear palsy and multiple system atrophy: More than a simple twist of fate?. Neuroscience Letters, 2009, 467, 208-211.	2.1	19

#	Article	IF	Citations
37	Cardiovascular diseases and hippocampal infarcts. Hippocampus, 2011, 21, 281-287.	1.9	18
38	LRP10 in Î±-synucleinopathies. Lancet Neurology, The, 2018, 17, 1032-1033.	10.2	11